Last reviewed · How we verify

NCT05673525

A Clinical Trial of the Transcatheter Aortic Valve Implantation System With a Prospective, Multi-Center, One-Arm Approach to Evaluate the Efficacy and Safety in the Treatment of Patients With Severe Aortic Stenosis

Not yet recruiting NA Last updated 6 January 2023
What this trial tests

NA trial testing Transcatheter Aortic Valve Implantation (KOKA-VALVE) in Aortic Stenosis in 131 participants. Not yet recruiting.

Timeline
30 December 2022
Primary endpoint
30 December 2024
30 December 2028

Quick facts

Lead sponsorChinese Academy of Medical Sciences, Fuwai Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment131
Start date30 December 2022
Primary completion30 December 2024
Estimated completion30 December 2028
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Who can join

65 and older, any sex, with Aortic Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Clinical Trial of the Transcatheter Aortic Valve Implantation System with a Prospective, Multi-Center, One-Arm Approach to Evaluate the Efficacy and Safety in the Treatment of Patients with Severe Aortic Stenosis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aortic Stenosis

Currently open trials in the same condition.

Other Chinese Academy of Medical Sciences, Fuwai Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05673525.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing